Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vincristine Strategies in Relapsed Childhood ALL
NCT00381680Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Mar 2007
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies, Lipid-based Nanoparticles, Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of vincristine sulfate liposome injection in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Children's Oncology Group. Primary endpoint: Event Free Survival at 3 years. Started Mar 2007; status: completed.
02
Drugs
vincristine sulfate liposome injection
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00381680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381680.